80 Hematologic Manifestations of Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome Flashcards

1
Q

HIV-1, the virus that causes AIDS, is a ___________ that originated as a simian immunodeficiency virus (SIV) in chimpanzees and entered the human population in the early 20th century in equatorial Africa

A

Lentivirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HIV-1 actually comprises four distinct viruses

A

Types M, N, O, and P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The viral type responsible for the HIV-1 pandemic, was detected in a tissue sample from 1959 and probably entered the human population in or around Kinshasa, Democratic Republic of Congo (then Leopoldville, Belgium Congo) between 1910 and 1930

A

Group M

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The result of cross-species transmission of SIV from sooty mangabeys to humans

A

HIV-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HIV1 or HIV2

Progress with disease more slowly and have lower plasma viral loads (often nondetectable)

A

HIV2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The globally predominant viral strain and is further divided into nine subtypes and many more recombinant viruses (circulating recombinant forms [CRFs]) with some geographic localization

A

Group M

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Geographic localization of Group M

Subtypes A and D:
Subtype C:
Subtype B:
CRF01:

A

Geographic localization of Group M

Subtypes A and D: East Africa
Subtype C: most prevalent subtype globally, in South Africa, India, and Asia
Subtype B: Caribbean, the Americas, and Western Europe
CRF01:Southeast Asia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Predominant mode of transmission in the following areas:

United States, Northern Europe, Australia, and parts of Central and South America:
Sub-Saharan Africa:
Southern and Eastern Europe and Southeast Asia:

A

Predominant mode of transmission in the following areas:

United States, Northern Europe, Australia, and parts of Central and South America: sexual contact between men

Sub-Saharan Africa: heterosexual spread

Southern and Eastern Europe and Southeast Asia:injection drug use followed by sexual transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Eighty percent of HIV infections occur via ____________________when cell-free and cell-associated virions transverse the epithelium to gain access to macrophages, Langerhans cells, dendritic cells, and CD4-expressing T lymphocytes.

A

Mucosal transmission during sex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

To infect most cells, HIV must bind to CD4 and one of two major coreceptors:

A

CCR5 or CXCR4

** In most cases, CCR5-utilizing viral strains are those that are transmitted and predominate early in disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Replication of HIV occurs in

A

tissue macrophages and dendritic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Typically, the asymptomatic phase of chronic infection will last for ________, although there is great interindividual variation dictated by the effectiveness of the immune response in controlling HIV replication

A

8 to 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Those who maintain CD4+ T-cell counts >500 for 5 years without therapy

A

Long-term nonprogressors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Those with low or nondetectable plasma HIV RNA without treatment

A

Elite controllers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tumors classified as AIDS-defining malignancies

A

Kaposi sarcoma
Cervical cancer
Certain subtypes of non-Hodgkin lymphoma (NHL) (initially Burkitt lymphoma)
Immunoblastic lymphoma
Primary CNS lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HIV STAGING: Infection within the previous 6 months

A

Stage 0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HIV STAGING: CD4 count ≥500 cells/μL (or ≥26%)

A

Stage 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

HIV STAGING: CD4 count 200–499 cells/μL
(or 14%–25%)

A

Stage 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

HIV STAGING: AIDS-defining condition or CD4 count <200 cells/μL (or <14%)

A

Stage 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Opportunistic Infections by CD4 Count

> 500 cells/μL

A

Any condition that can occur in HIVuninfected
persons, eg, bacterial pneumonia, tuberculosis, varicella zoster, herpes simplex virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Opportunistic Infections by CD4 Count

350–499 cells/μL

A

Thrush, seborrheic dermatitis, oral hairy
leukoplakia, molluscum contagiosum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Opportunistic Infections by CD4 Count

200–349 cells/μL

A

Kaposi sarcoma, lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Opportunistic Infections by CD4 Count

100–199 cells/μL

A

Pneumocystis pneumonia, Candida esophagitis, cryptococcal meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Opportunistic Infections by CD4 Count

<100 cells/μL

A

Toxoplasma encephalitis, disseminated, Mycobacterium avium complex, progressive
multifocal leukoencephalopathy, cytomegalovirus retinitis, primary CNS lymphoma, microsporidia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

TRUE OR FALSE

All HIV-infected persons be offered ART regardless of CD4 count

A

TRUE

All HIV-infected persons be offered ART regardless of CD4 count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Primary Prophylaxis: Pneumocystis pneumonia

CD4 <200 cells/μL or <14% or oral candidiasis or an AIDS-defining illness

A

Trimethoprimsulfamethoxazole or dapsone or
aerosolized pentamidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Primary Prophylaxis: Tuberculosis

Purified protein derivative >5 mm or positive
interferon-γ release assay

A

Isoniazid and pyridoxine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Primary Prophylaxis: Toxoplasmosis

Immunoglobulin G+ and CD4 <100 cells/μL

A

Trimethoprimsulfamethoxazole or dapsone plus pyrimethamine plus leucovorin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Primary Prophylaxis: Mycobacterium avium complex

CD4 <50 cells/μL

A

Azithromycin or Clarithromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

An acute inflammatory reaction as a result of reconstitution of the immune system in the presence of organisms or foreign antigens

A

Immune reconstitution inflammatory syndrome (IRIS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Risk factors for the development of IRIS

A

Low baseline CD4 count
More severe disease
A short interval between treatment of the opportunistic infection and initiation of ART

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Treatment of IRIS

A

Treatment of the underlying infection or condition
Continued ART
Antiinflammatory medication, such as glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

The impediment to cure for nearly all HIV-infected people

A

The persistence of replication-competent but transcriptionally silent HIV proviral DNA in long-lived resting cells (the HIV latent reservoir)

34
Q

TRUE OR FALSE

All patients who present to the hematologist with NHL, Hodgkin lymphoma, idiopathic thrombocytopenic purpura (ITP), or other malignancies should be tested for HIV

A

TRUE

All patients who present to the hematologist with NHL, Hodgkin lymphoma, idiopathic thrombocytopenic purpura (ITP), or other malignancies should be tested for HIV

**5% of those with diffuse large B-cell lymphoma (DLBCL) and 22% of patients with Burkitt lymphoma in the United States are HIV-positive

35
Q

The most common malignancy in people living with HIV worldwide.

A

Kaposi sarcoma

36
Q

AIDS-Defining Malignancies and Oncogenic Viruses

Kaposi sarcoma:
Aggressive non-Hodgkin lymphoma:
Primary CNS lymphoma:
Invasive cervical cancer:

A

AIDS-Defining Malignancies and Oncogenic Viruses

Kaposi sarcoma: HHV8
Aggressive non-Hodgkin lymphoma: EBV, HHV8
Primary CNS lymphoma: EBV
Invasive cervical cancer: HPV

37
Q

TRUE OR FALSE

HIV-associated Burkitt lymphoma is approximately one-third as common as HIV-associated DLBCL in the Western world, and occurs at a lower CD4 count.

A

FALSE

HIV-associated Burkitt lymphoma is approximately one-third as common as HIV-associated DLBCL in the Western world, and occurs at a HIGHER CD4 count.

38
Q

Burkitt lymphoma in HIV-negative people, and involves translocation of the _____________ with one of the immunoglobulin (Ig) genes on chromosomes 2, 14, or 22, resulting in overexpression of Myc

A

Myc gene on chromosome 8

39
Q

More than ______of patients with HIV-associated Burkitt lymphoma present with stage IV disease and extranodal sites are often involved.

A

More than 80%

40
Q

A common feature of CNS involvement of Burkitt lymphoma

A

Cranial nerve palsies

41
Q

TRUE OR FALSE

As in the HIV-negative setting, CHOP is not adequate treatment for Burkitt lymphoma and should not be used.

A

TRUE

As in the HIV-negative setting, CHOP is not adequate treatment for Burkitt lymphoma and should not be used.

42
Q

Primary CNS lymphoma in HIV-positive patients usually have a CD4 count of less than_______

A

CD4 count of less than 50 cells/μL and often of less than 20 cells/μL.

43
Q

The pathophysiology of HIV-associated primary CNS lymphoma is related to _______ virus, which is detectable in virtually all case

A

EBV

44
Q

The pathophysiology of HIV-associated primary CNS lymphoma is related to _______ virus, which is detectable in virtually all case

A

EBV

45
Q

In one series, the most common symptom of CNS lymphoma

A

Headache

46
Q

Characteristic features on magnetic resonance imaging of the brain in primary CNS lymphoma

A

A single to several mass lesions in the subcortical white matter

47
Q

Anatomic sites commonly involved are predominantly in primary CNS lymphoma

A

Cerebral cortex and periventricular area

Cerebellar or brainstem involvement is rare

48
Q

TRUE OR FALSE

Detection of EBV in the CSF supports, but does not confirm, the diagnosis of primary CNS lymphoma

A

TRUE

Detection of EBV in the CSF supports, but does not confirm, the diagnosis of primary CNS lymphoma

49
Q

Can help distinguish primary CNS lymphoma from other common causes of focal brain lesions in profoundly immunosuppressed patients with HIV, namely, cerebral toxoplasmosis and other infections.

A

PET-CT of the brain

50
Q

A rare and very aggressive B-cell NHL with plasmacytic differentiation that often involves the oral cavity, typically the gingiva and the palate.

A

Plasmablastic lymphoma

51
Q

An aggressive B-cell lymphoma characterized by lymphomatous effusions in body cavities, most commonly pleural effusion, followed by ascites and pericardial effusion or multiple body cavities; lymph nodes, marrow, and skin can also be involved.

A

Primary effusion lymphoma (PEL)

52
Q

A solid variant of PEL that presents without effusion, but with lymph node, gastrointestinal, skin, or liver involvement and shares epidemiologic and immunophenotypic characteristics with the classical PEL.

A

Extracavitary PEL

53
Q

100% of PEL are ___________–positive and approximately 80% are EBV-positive

A

human herpesvirus-8 (HHV8)

54
Q

HHV8 plays a key pathophysiologic role, possibly by elaboration of a viral homologue of _______ and a viral homologue of ____________

A

FLICE inhibitory protein
interleukin (IL)-6

55
Q

Other HHV8-related disorders

A

Castleman disease
Kaposi sarcoma
Aggressive NHL

56
Q

ART that causes marrow suppression and should be avoided in patients receiving myelosuppressive chemotherapy

A

Zidovudine

57
Q

A rare polyclonal lymphoproliferative disorder characterized by periodic flares (an inflammatory illness accompanied by lymphadenopathy and splenomegaly), and a high risk of progression to lymphoma

A

Castleman disease

58
Q

The pathophysiology of Castleman disease is related to

A

IL-6

59
Q

The morphology of multicentric Castleman disease in HIV-positive patients

A

Plasmablastic cells in the mantle zone of the follicles; HHV8 is detectable in the plasmablasts

60
Q

The backbone of treatment of Castleman disease

A

Rituximab

61
Q

An anti–IL-6 monoclonal antibody approved by the FDA for treatment of Castleman disease in HIV-negative patients but not in HIV-positive patients

A

Siltuximab

62
Q

An anti–IL-6 receptor monoclonal antibody FDA-approved for use in rheumatoid arthritis but not for treatment of Castleman disease

A

Tocilizumab

63
Q

Most common lymphoma in patients with HIV

A

DLBCL

64
Q

A syndrome characterized by an inflammatory illness similar to a flare of Castleman disease, but without the pathologic diagnosis of Castleman disease

A

KSHV-associated inflammatory cytokine syndrome (KICS)

65
Q

Immunohistochemical and Molecular Diagnostic Findings

Diffuse large-B-cell lymphoma

A

Immunohistochemical and Molecular Diagnostic Findings

Diffuse large-B-cell lymphoma: CD20+, may have c-myc translocation

66
Q

Immunohistochemical and Molecular Diagnostic Findings

Burkitt’s lymphoma

A

CD20+, CD10+, c-myc translocation

67
Q

Immunohistochemical and Molecular Diagnostic Findings

AIDS-related primary CNS lymphoma

A

CD20+, EBV+

68
Q

Immunohistochemical and Molecular Diagnostic Findings

Primary effusion lymphoma

A

DC20−, KSHV+, EBV+ (in approximately 80% of cases)

69
Q

Immunohistochemical and Molecular Diagnostic Findings

Plasmablastic lymphoma

A

CD20−, EBV+, may have c-myc translocation

70
Q

Immunohistochemical and Molecular Diagnostic Findings

KSHV-associated multicentric Castleman’s disease

A

KSHV+, lambda-restricted plasmablasts; a proportion of infected cells are viral IL-6+

71
Q

Immunohistochemical and Molecular Diagnostic Findings

Classic Hodgkin lymphoma

A

Often EBV+, Reed-Sternberg cells

72
Q

Results from failure to regulate the immune response, resulting in excess activation of T lymphocytes, increased cytokine secretion, and hyperactivation of macrophages

A

Hemophagocytic syndrome

73
Q

An ART that can cause macrocytic anemia and leukopenia and is not commonly used at present because of its toxicity.

A

Zidovudine

74
Q

Prophylactic drug used for P. jiroveci prophylaxis, can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency

A

Dapsone or trimethoprim-sulfamethoxazole

75
Q

Drug used to treat herpes simplex virus, varicella zoster, CMV, and sometimes HHV8, often cause pancytopenia.

A

Ganciclovir or valganciclovir

76
Q

Drug for PCP prophylaxis that can also cause myelosuppression and pancytopenia

A

Trimethoprim-sulfamethoxazole

77
Q

The optimal treatment for HIV-associated anemia

A

Initiation of ART

78
Q

An FDA-approved indication for erythropoietin in HIV patients

A

Anemia caused by zidovudine and an erythropoietin level of 500 mU/mL or less

79
Q

The primary treatment of HIV-associated ITP

A

Initiation of ART

ART typically takes 3 months to improve the platelet counts

80
Q

Treatment option in HIV-associated ITP with severe thrombocytopenia, Rh+ and has an intact spleen

A

IV anti-D

81
Q

Major side effect of anti-D treatment

A

Drop in the hemoglobin (significant hemolysis)

82
Q

TRUE OR FALSE

In HIV-associated ITP, glucocorticoids are less attractive because of the potential to decrease CD4 counts, increase the risk of infection, and increase the risk of Kaposi sarcoma progression.

A

TRUE

In HIV-associated ITP, glucocorticoids are less attractive because of the potential to decrease CD4 counts, increase the risk of infection, and increase the risk of Kaposi sarcoma progression.